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Background: Althoughprevious studies have shown that peripheral airwayobstruction can occur in
idiopathic PAH (IPAH), pulmonary function tests have not been well-studied in patients with PAH
associated with congenital heart disease (CHD-PAH) and connective tissue disease (CTD-PAH).
Methods: A multicenter prospective study was performed in PAH patients in China. Pulmonary
function tests were evaluated in 190 PAH patients.
Results: Total lung capacity (TLC), residual volume (RV) and total airway resistance (Rtot) were
similar in PAH patients and controls. However, measures of airflow, including vital capacity
(VC), forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1/FVCandMEF50were
decreased in PAH group. Single-breath diffusion capacity for carbon monoxide (DLCO) was also
decreased in PAH patients. Expiratory flowevolume curves showed reduction and a curvilinear
appearance in patients with PAH. Similar changes were observed among the various subgroups
of IPAH, CHD-PAH, and CTD-PAH patients. More CTD-PAH patients had abnormal DLCO.
Conclusions: Airway obstruction is common in IPAH, CHD-PAH and CTD-PAH patients. CTD-PAH
patients have lower DLCO. Hemodynamics, serum markers and exercise capacity parameters did
not correlate well with pulmonary function indices.
ª 2009 Elsevier Ltd. All rights reserved.of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University, No. 507 Zhengmin Road,
il.com (Z.-C. Jing).
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disease, such as chronic obstructive or interstitial lungPulmonary arterial hypertension (PAH) is a condition char-
acterized by pulmonary vascular growth and proliferation,
leading to increased pulmonary vascular resistance and
right heart dysfunction.1 Previous studies have shown that
idiopathic PAH (IPAH), and PAH occurring in association with
congenital heart disease (CHD-PAH) and connective tissue
disease (CTD-PAH) have similar pathologies such as medial
hypertrophy of muscular and elastic arteries, dilation and
intimal atheromas of elastic pulmonary arteries and right
ventricular hypertrophy.2 In addition, Giaid et al studied
the distribution of endothelin-1 in lung specimens in
pulmonary hypertension patients and found IPAH, CHD-PAH
and CTD-PAH are all associated with the increased expres-
sion of endothelin-1 in vascular endothelial cells, suggest-
ing that the production of endothelin-1 may contribute to
pulmonary hypertension.3 Considering the proximity of
pulmonary vasculature and peripheral airways, it is possible
that the latter may be affected either by mechanical
encroachment of enlarged vessels or by mediators of
increased smooth muscle tone or proliferation.4
Because peripheral airways affected follow the pulmo-
nary vasculature, it is reasonable to postulate that pulmo-
nary function might be affected by the development of
pulmonary hypertension. However, previous studies of
pulmonary function in primary pulmonary hypertension (PPH)
(or IPAH) have been contradictory, with normal lung volumes,
restrictive ventilatory pattern, and airway obstruction.5e7 In
a German study of PPH, peripheral airway obstruction was
common, but that study did not include CHD-PAH and
CTD-PAH.7 Pulmonary function tests have not been well-
studied in patients with CHD-PAH and CTD-PAH and the
mechanismofchanges inpulmonary function remainsunclear.
This cross sectional study was designed to identify
pulmonary function characteristics in different forms of PAH,
including IPAH, CHD-PAH and CTD-PAH, and to explore the
relationship among pulmonary function parameters, hemo-
dynamic parameters, serum markers and exercise capacity.Patients and methods
Patients
This is a multicenter prospective study assessing pulmonary
function indices in IPAH, CHD-PAH, and CTD-PAH from June
2006 to February 2008. The study protocol was reviewed
and approved by Shanghai Pulmonary Hospital’s ethics
committee. Informed consent was obtained from all
individuals.
Patients with PAH were distributed into three diagnostic
groups using the Venice classification criteria: (a) idiopathic,
no etiologic agent identified; (b) congenital heart disease
diagnosed by way of hemodynamic assessment and echo-
cardiography; and (c) connective tissue disease in accor-
dance with conventional clinical criteria.8
One hundred and ninety patients with PAH were enrolled
in this study. Only patients who had undergone pulmonary
function tests and cardiac catheterization within 30 days
were included. None of the patients had a history of lungdisease, lung cancer, or extensive tuberculosis. Fifty-six
non-smoking adult volunteers without pulmonary or cardiac
dysfunction and matched for age and sex were enrolled as
control group to compare with patients with PAH. Pulmo-
nary function indices were also compared among three
diagnostic subgroups of PAH.
According to WHO functional classification at enroll-
ment, all PAH patients were divided into two groups: Class
II and Class III/IV. Clinical manifestations, RHC and pulmo-
nary function indices were compared between two groups.
Six-minute walk distance, pulmonary function test
and hemodynamic measurements
Six-minute walk tests were performed in accordance with
the American Thoracic Society guidelines.9 Pulmonary
function tests were carried out using Master Screen Diffu-
sion (Erich Jaeger Inc., Germany) according to standard
protocols.10 Pulmonary function indices including lung
volumes, flow/volume curves, single-breath diffusion
capacity for carbon monoxide (corrected for haemoglobin
levels) and total airway resistance were determined with
the patients sitting upright and breathing through a flanged
mouthpiece inside the lips. The results were expressed as
percent of predicted (% pred).
Right heart catheterization was performed through
SwaneGanz catheter (Edwards Lifesciences World Trade
Co., Ltd, USA) in all enrolled PAH patients according to
standard procedures.11 Baseline hemodynamic variables
were measured including right atrial pressures, pulmonary
arterial pressures, pulmonary capillary wedge pressures,
and systemic pressures. Cardiac output (CO) was measured
by the Fick’s principle or themodilution method and cardiac
index (CI) was calculated by CO divided body surface area.
Pulmonary vascular resistance (PVR) was calculated using
the standard formula and was expressed in Wood units.
Statistical analysis
SPSS 13.0 software was applied in data management (SPSS
Inc, Chicago, Illinois). The data were expressed as
mean SD or frequency and proportions. Differences
between proportions were compared with a c2 test; differ-
ences between two groups were assessed by independent
sample t test; differences among multiple groups were
performed by ANOVA. Multivariate regression analysis was
performed to determine the independent association of
clinical variables with pulmonary function indices. Correla-
tion coefficients among pulmonary function parameters,
hemodynamic parameters, 6 MWD, and serum markers are
expressed as Spearman correlation coefficients. A p value
less than 0.05 was considered to be significant.
Results
Baseline characteristics of study population
The clinical characteristics of PAH patients and controls
were summarized in Table 1. The PAH patients population
Table 1 Clinical characteristics of controls and all PAH
patients.
Control All PAH
Total number (n) 56 190
Sex (male/female) 21/35 50/140
Age (years) 34.80 10.02 31.78 11.28
Height (cm) 162.66 8.40 162.52 7.65
Weight (kg) 58.96 14.12 55.17 11.69
1138 Z.-C. Jing et al.did not differ from the controls in age, sex, height and
weight (p> 0.05). Five male patients (2 IPAH, 3 CHD-PAH)
had a smoking history before onset, and all have quit
smoking after onset of breathless. No female patients had
smoking history.
Pulmonary function test comparison between
controls and PAH patients
Compared with controls, lung volumes were normal in all
patients. Total lung capacity (TLC), residual volume (RV),
functional residual capacity (FRC) and total airway resis-
tance (Rtot) in PAH patients were close to controls and
predicted values (Table 2).
Inspiratory vital capacity (VC), forced inspiratory vital
capacity (FVC), forced expiratory volume in 1 s (FEV1) and
the ratio of FEV1/FVC were reduced compared with
controls (Table 2). The mean expiratory flow rates at 50%
(MEF50) were 79.96 20.72% predicted in controls and
55.18 23.80% predicted in PAH patients. Furthermore, the
flowevolume curves indicated considerable peripheral
airflow obstruction in PAH patients (Fig. 1). All these results
showed that there was moderate peripheral airway
obstruction in PAH patients.
The single-breath diffusion capacity for carbon
monoxide (DLCO) in PAH patients was 65.59 19.64% pre-
dicted, which was significantly decreased compared with
that of controls (85.32 19.37% predicted).Table 2 The comparison of pulmonary function indices in patie
All PAH (nZ 190) Contro
TLC (% predicted) 88.46 12.15 91.98
VC (% predicted) 82.57 14.58 93.23
FVC (% predicted) 83.86 14.80 95.63
FEV1 (% predicted) 78.08 15.86 91.29
FEV1/FVC (% predicted) 95.30 11.00 99.88
RV (% predicted) 96.85 19.41 92.89
MEF50 (% predicted) 55.18 23.80 79.96
FRC (% predicted) 92.22 15.70 94.93
Rtot (% predicted) 112.85 24.09 111.08
DLCO (% predicted) 65.74 19.86 85.32
FVC/DLCO 1.37 0.41 1.18
TLC, total lung capacity; VC, vital capacity; FVC, forced vital capacity
functional residual capacity; MEF50, maximal expiratory flow 50% of e
capacity for carbon monoxide (corrected for haemoglobin levels). Va
predicted values (% pred).Baseline characteristics comparison among IPAH,
CHD-PAH and CTD-PAH patients
At right heart catheterization, all PAH patients showed
moderate-to-severe pulmonary hypertension and pulmo-
nary capillary wedge pressure was normal. Patients with
PAH were classified according to different etiologies. Mean
age was 34.98 11.39 years in IPAH, 28.66 10.80 years in
CHD-PAH and 34.07 10.43 years in CTD-PAH. The male/
female ratio among each PAH group was similar. The height
and weight were similar among different PAH groups. The
ratio of WHO functional Class II and IIIeIV was similar
among the three groups, and 6-min walk distance showed
no significant difference among three PAH groups. The
serum markers such as uric acid (UA) were similar among
the three PAH groups. Brain natriuretic peptide (BNP) and
endothelin-1 (ET-1) in CHD-PAH group were lower than
those in IPAH group and CTD-PAH group. SaO2 (arterial
oxygen saturation) and SvO2 (mixed venous oxygen satura-
tion) were similar between IPAH and CTD-PAH. But SaO2 was
lower and SvO2 was higher in CHD-PAH than other two
groups, this may be caused by left-to-right or right-to-left
intracardiac shunting in CHD-PAH (see Table 3).
The results of hemodynamic assessment are shown in
Table 3. Mean pulmonary artery pressure (PAP) in the CHD-
PAH group was 75.08 20.75 mmHg, which was significantly
higher than that in the IPAH group (59.90 17.07 mmHg;
p< 0.001) and the CTD-PAH group (54.92 15.80 mmHg;
p< 0.001); CI in CHD-PAH group was 3.22 1.29 l/min/m2
and significantly higher than 2.50 0.99 l/min/m2 in the
IPAH group (p< 0.001) and 2.50 0.93 l/min/m2 in the CTD-
PAH group (p< 0.001); the RAP and PVR among the three
groups showed no statistical difference.
Pulmonary function indices comparison among
IPAH, CHD-PAH and CTD-PAH patients
The indices of pulmonary function test in different etiolo-
gies of PAH were also compared. After adjustment for age
and sex, mPAP, CI, BNP, and ET-1 level, lung volumes suchnts with all PAH patients and controls.
l (nZ 56) Mean difference (95% CI) p-Value
 11.26 3.52 (0.08 to 7.12) 0.06
 13.70 10.68 (2.12e6.36) <0.001
 14.16 11.76 (7.38e16.15) <0.001
 17.20 13.21 (8.36e18.05) <0.001
 8.83 4.57 (1.75e7.40) 0.002
 21.70 3.96 (10.37 to 2.46) 0.22
 20.72 24.78 (17.85e31.72) <0.001
 20.39 2.71 (2.35 to 7.77) 0.29
 16.05 1.76 (8.15 to 4.62) 0.58
 19.37 19.58 (13.67e25.50) <0.001
 0.32 0.19 (0.09e0.29) <0.001
; FEV1, forced expiratory volume in 1 s; RV, residual volume; FRC,
xhaled VC; Rtot, airway resistance; DLCO, single-breath diffusion
lues are expressed as mean SD and percentage of measured to
Figure 1 Flowevolume curve of a 25-year-old non-smoking
man with idiopathic pulmonary arterial hypertension (IPAH).
Predicted values (bar) for individual forced vital capacity are
also shown.
Pulmonary function testing in PAH 1139as TLC, FEV1/FVC, and Rtot were similar in the three PAH
groups (Table 4).
Compared with the IPAH group, VC, FVC, FEV1 and MEF50
were decreased in the CHD-PAH group. RV and FRC were
slightly decreased in the CTD-PAH compared with IPAH and
CHD-PAH, indicating that mild restrictive abnormalities
exist in the CTD-PAH group. All three groups demonstrated
decreased DLCO. Compared with IPAH and CHD-PAH, the
CTD-PAH group showed the greatest abnormality in DLCO.Table 3 Clinical characteristics of different PAH patients.
IPAH
Total number (n) 62
Sex (male/female) 18/44
Age (years) 34.98 11.39
Height (m) 163.71 8.09
Weight (kg) 59.44 12.83
WHO-FC (II/IIIeIV) 26/36
Six-min walk distance (m) 417.34 94.41
Hemodynamics
RAP (mmHg) 5.62 4.89
mPAP (mmHg) 59.90 17.07
PVR (Wood Units) 15.65 8.13
CI (l/min/m2) 2.50 0.99
UA (mmol/l) 360.07 104.50
BNP (fmol/ml) 1176.18 984.63
ET-1 (fmol/ml) 0.91 0.60
SaO2 (%) 92.61 6.28
SvO2 (%) 63.77 12.43
RAP, right atrial pressure; mPAP, mean pulmonary artery pressure; P
World Healthy Organization Functional Class; UA, uric acid; BNP, bra
saturation; SvO2, mixed venous oxygen saturation. Other abbreviation
*p< 0.05, **p< 0.01 vs. IPAH group using one-way ANOVA or Chi-squa
#p< 0.05, ##p< 0.01 vs. CHD-PAH group using one-way ANOVA or ChiPulmonary function comparison between
WHO-FC II, and IIIeIV
There were no significant differences in TLC, VC, FVC, FEV1,
FEV1/FVC, RV, MEF50 and Rtot between the WHO-FC II group
and IIIeIV group (see Table 5). Only DLCO in WHO-FC IIIeIV
group was significantly decreased compared with WHO-FC II
(61.11 18.86 vs. 71.46 19.68% predicted, p< 0.001).
If grouped by mean right atrial pressure, mean pulmo-
nary arterial pressure and mean interval time from onset of
symptoms to diagnosis, there were no differences in
pulmonary function indices (data not shown).
Correlations of pulmonary function indices with
hemodynamics, serum markers and exercise
capacity
Correlations of selected pulmonary function indices among
hemodynamics, serum markers and exercise capacity were
shown in Table 6. No pulmonary function indices correlated
well with hemodynamics or serum markers or exercise
capacity findings.
The FEV1 had a mild and moderate correlation, with ET-1
of 0.24, and with 6MWD of 0.20 (Fig. 2). CI had a moderate
correlation with DLCO (rZ 0.24). DLCO had a positive corre-
lation with 6-min walk distance and a negative correlation
with ET-1, the correlation coefficient was 0.27 and 0.24,
respectively.
Discussion
This study confirms previous studies suggesting that
peripheral airway obstruction occurs in IPAH.7,12,13 Our studyCHD-PAH CTD-PAH
91 37
25/66 7/30
28.66 10.80** 34.07 10.43#
161.65 7.52 162.65 7.10
51.40 9.29 57.27 12.29
47/44 13/24
426.26 98.59 381.25 114.25
5.14 3.88 5.59 4.98
75.08 20.75** 54.92 15.80##
16.59 8.83 13.06 7.65
3.22 1.29** 2.50 0.93##
353.98 111.19 347.98 115.79
773.72 688.65* 1244.21 1156.23#
0.69 0.49* 0.92 0.55#
86.79 9.37** 92.67 4.53##
72.73 10.22** 59.81 12.06##
VR, pulmonary vascular resistance; CI, cardiac index; WHO-FC,
in natriuretic peptide; ET-1, endothelin-1; SaO2, arterial oxygen
s are as in Table 2.
re test.
-square test.
Table 4 The comparison of pulmonary function indices in patients with IPAH, CHD-PAH and CTD-PAH.
IPAH (nZ 62) CHD-PAH (nZ 91) CTD-PAH (nZ 37)
TLC (% predicted) 90.71 1.65 88.26 1.46 84.68 2.15
VC (% predicted) 86.91 1.91 80.16 1.70* 80.43 2.47
FVC (% predicted) 88.86 1.91 81.58 1.70* 80.30 2.47*
FEV1 (% predicted) 83.09 2.05 74.15 1.82** 76.83 2.65*
FEV1/FVC (% predicted) 97.09 1.39 92.76 1.23 97.78 1.78
RV (% predicted) 100.18 2.34 99.19 2.06 84.55 2.99**##
MEF50 (% predicted) 61.50 2.91 50.06 2.59* 57.60 3.76
FRC (% predicted) 94.48 1.95 93.62 1.72 83.48 2.49**##
Rtot (% predicted) 108.62 3.27 114.00 2.85 116.64 4.14
DLCO (% predicted) 62.92 2.47 71.21 2.20 56.35 3.20##
FVC/DLCO 1.52 0.45 1.20 0.31** 1.53 0.41##
Abbreviations are as in Table 2.
*p< 0.05, **p< 0.01 vs. IPAH group using one-way ANOVA.
#p< 0.05, ##p< 0.01, vs. CHD-PAH group using one-way ANOVA.
Multivariate analysis controlling for age, sex, mPAP, CI, BNP, and ET-1.
Table 5 The comparison of pulmonary function indices in
patients with WHO-FC II, and III/IV.
WHO-FC II
(nZ 86)
WHO-FC IIIeIV
(nZ 104)
TLC (% predicted) 89.52 9.85 87.63 13.67
VC (% predicted) 84.79 14.33 80.77 14.60
FVC (% predicted) 86.03 14.04 82.11 15.23
FEV1 (% predicted) 79.95 13.52 76.57 17.44
FEV1/FVC (% predicted) 95.52 9.01 95.13 12.41
RV (% predicted) 97.19 21.25 96.58 17.90
MEF50 (% predicted) 56.06 23.38 54.46 24.22
FRC (% predicted) 93.31 15.51 91.34 15.87
Rtot (% predicted) 114.74 22.54 111.36 25.25
DLCO (% predicted) 71.46 19.68 61.11 18.86**
Abbreviations are as in Table 2.
**p< 0.01 vs. WHO-FC II group using Chi-square test.
1140 Z.-C. Jing et al.also showed that peripheral airway obstruction occurs in
CHD-PAH and CTD-PAH. Peripheral airflow obstruction was
indicated by reduction in the MEF50 to 55.18 23.80 pre-
dicted. After being divided by different etiologies, the most
serious obstructive abnormality was observed in CHD-PAH,
then CTD-PAH, and lastly IPAH. CTD-PAH also showed mild
restrictive abnormalities. Following worsening WHO func-
tion class, DLCO decreased sharply. There was no more than
moderate correlation between pulmonary function indices
and serum or hemodynamic parameters.
Peripheral airway obstruction is common in PAH
patients. Our study confirmed that peripheral airway
obstruction is the most striking characteristics of pulmo-
nary function test in IPAH, CHD-PAH and CTD-PAH patients;
MEF50 may be the best index to describe the severity of
obstruction. These findings are in agreement with the study
of Meyer. Their study showed that in PPH patients, TLC was
almost normal, RV increased and VC decreased.7 Our study
showed that not only IPAH but also CHD-PAH and CTD-PAH
showed peripheral airway obstruction. However, we could
not confirm that peripheral airway obstruction was more
pronounced in severe disease as described in Meyer’s study.
The earliest change associated with peripheral airway
obstruction is thought to be a slow-down in the terminal
portion of the spirogram, even when the initial part of the
spirogram is barely affected.14 This slow-down of expira-
tory flow is most obviously reflected in a concave shape of
the flowevolume curve. Quantitatively, it is reflected in
a proportionally greater reduction in the instantaneous flow
measured at 50% of the FVC exhaled than in FEV1. MEF50 has
been used by many authors as a sensitive index of periph-
eral airflow limitation in chronic obstructive pulmonary
disease, in occupational lung disease or in primary pulmo-
nary hypertension.12,15,16 In our study, MEF50 was signifi-
cantly decreased in all PAH groups as compared to the
control group. Compared among different etiologies of
PAH, MEF50 was 59.52 24.27% predicted in IPAH,
48.89 27.45% predicted in CHD-PAH and 59.95 33.92%
predicted in CTD-PAH indicating that peripheral airway
obstruction is common in IPAH, CHD-PAH and CTD-PAH.
Considering all PAH patients, the airway resistance as
a whole did not differ significantly from healthy controls.This is plausible since airflow resistance is rarely used to
identify airflow obstruction in clinical practice. It is more
sensitive for detecting narrowed extrathoracic or large
central intrathoracic airways than peripheral intrathoracic
airways.14 Data from asthmatics show that even major
obstruction of peripheral airways can occur without
recognized increases of airway resistance.17
Probable causes of peripheral airway obstruction
In most of our PAH patients, MEF50 was reduced compared
with the control group. The underlying cause of peripheral
airway obstruction in PAH is still unknown. In the early 1980s,
some authors interpreted the finding of peripheral airflow
obstruction as merely a result of the pathological changes in
the pulmonary vasculature.18 Although the true reason is still
unclear, those studies may not fully explain the cause of
peripheral airway obstruction in PAH. Researchers havebegun
to question whether abnormal endothelial function may play
an important role in the cause of peripheral airway obstruc-
tion. Abnormalities in endothelial function, including
impaired production of prostacyclin and nitric oxide and
excessive synthesis of endothelin have well-known effects on
Table 6 Correlation of pulmonary function indices with hemodynamics, serum markers and exercise capacity.
VC % DLCO % FEV1 % MEF50 % FEV1/FVC FVC/DLCO
mPAP 0.07 0.13 0.04 0.02 0.004 0.18*
PVR 0.19* 0.10 0.19* 0.15 0.03 0.03
CI 0.09 0.24** 0.13 0.12 0.04 0.13
UA 0.15* 0.01 0.06 0.01 0.02 0.04
BNP 0.23** 0.09 0.18* 0.09 0.06 0.05
ET-1 0.29** 0.24** 0.24** 0.15 0.006 0.07
6MWD 0.27** 0.27** 0.20** 0.08 0.01 0.14
Abbreviations are as in Tables 2 and 3.
*p< 0.05; **p< 0.01.
Pulmonary function testing in PAH 1141the bronchial system.19e21 Endothelin-1 mimics several
features of asthma, including bronchospasm, airway remod-
elling, inflammatory cell recruitment and activation, edema,
mucus secretion and airway dysfunction. ET-1 also possesses
mitogenic effects on smooth muscle cells and fibroblasts and
is a very potent bronchoconstrictor.3,19 Thus, the observed
peripheral obstruction may be a result of some spill over of
endothelin from the vasculature into the airway system. A
recent study, examining the effect of the endothelin receptor
antagonist bosentan on endothelin-induced bronchocon-
striction, showed that bosentan completely prevented ET-
receptor agonist (IRL1620) induced bronchoconstriction.22
Spiekerkoetter et al. found that inhaled salbutamol has
beneficial acute effects on pulmonary function, blood gases
and hemodynamics in patients with primary pulmonary
hypertension.12 Their studiesmay be helpful in understanding
the mechanism of peripheral airway obstruction in PAH, and
may suggest another therapeutic target in patients with PAH.
Probable causes of reduction in DLCO
In our study, hemodynamics, serum markers and exercise
capacity parameters did not correlate well with DLCO and
other pulmonary function indices. The mechanism under-
lying decreased DLCO in PAH remains to be elucidated. DLCO40
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R-Square = 0.06
Figure 2 Relationship between FEV1 and ET-1. A moderate neg
between FEV1 and 6MWD. A moderate positive correlation is seenhas been primarily considered a marker of capillary surface
area. Studies support the concept that reduced DLCO in
IPAH, CHD-PAH and CTD-PAH can be explained by the
increase in alveolar capillary membrane thickness, which
may caused by the proliferation of endothelial cells.23 The
reduction of perfused pulmonary capillary bed may fit the
pathological findings described at the Third World Sympo-
sium on Pulmonary Artery Hypertension: all forms of
pulmonary hypertension have some common pathologic
features regardless of their etiologies, that is to say, medial
hypertrophy of muscular and elastic arteries, dilation and
intimal atheromas of elastic pulmonary arteries.24
Clinical implications
The negative correlations of the FEV1 and DLCO with ET-1
are difficult to explain. Previous studies have shown that
ET-1 is an important factor involved in the pathogenesis of
PAH. Further investigation is needed to determine whether
ET-1 is involved in the pathogenesis of airway abnormali-
ties. DLCO has positive correlation with 6-min walk
distance. Our results concur with Sun’s study,25 which
found a proportional reduction in DLCO supporting the
finings that the primary pathological process involves the
blood vessels of the lungs. But we did not agree with40
60
80
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V
1.
0
R-Square = 0.04
200 300 400 500 600
6MWD
ative correlation is seen (r2Z 0.06, left figure); relationship
(r2Z 0.04, right figure).
1142 Z.-C. Jing et al.Steenhuis’s study, which showed that an increased pulmo-
nary vascular resistance was associated with a decrease in
pulmonary membrane diffusion capacity.26 Previous
evidence suggests that PAH is strongly associated with
a FVC/DLCO (% predicted) ratio of greater than 1.4,
27 but in
our study the correlation coefficient of mPAP with FVC/
DLCO was only 0.18. Further studies are needed to explain
the difference.
In conclusion, the notable characteristics of pulmonary
function tests in PAH were peripheral airway obstruction
and reduced diffusing capacity for carbon monoxide. MEF50
may be the most important measurement to evaluate
peripheral airway obstruction in pulmonary arterial hyper-
tension. No hemodynamic measurements, serum markers or
exercise capacity parameters correlated well with pulmo-
nary function indices. Pulmonary function testing has
limited value to predict hemodynamics in pulmonary arte-
rial hypertension and limited value in diagnosis of IPAH,
CHD-PAH and CTD-PAH. These findings suggest that further
studies are indicated.
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